FDA Approves WEGOVY — Novo Nordisk Pharmaceutical Industries, LP

# FDA Approves Novo Nordisk's Oral Semaglutide (Wegovy) Novo Nordisk Pharmaceutical Industries, LP received FDA approval for the oral formulation of semaglutide (Wegovy) on December 22, 2025, potentially expanding the GLP-1 agonist market by offering patients a convenient alternative to injectable weight-loss treatments. The approval could significantly strengthen Novo Nordisk's competitive position in the rapidly growing obesity treatment segment, though it may also intensify pricing pressures and competition from other oral GLP-1 candidates in